Comparative Pharmacology
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus UROXATRAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE versus UROXATRAL.
DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE vs UROXATRAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dutasteride inhibits both type 1 and type 2 isoforms of 5α-reductase, preventing conversion of testosterone to dihydrotestosterone (DHT), reducing prostate volume. Tamsulosin is a selective antagonist of alpha-1A and alpha-1D adrenoceptors, relaxing smooth muscle in the prostate and bladder neck.
Selective antagonist of postsynaptic alpha1A-adrenoceptors in the prostate, bladder base, and prostatic urethra, leading to relaxation of smooth muscle and improved urinary flow.
One capsule (dutasteride 0.5 mg / tamsulosin hydrochloride 0.4 mg) orally once daily, approximately 30 minutes after the same meal each day.
10 mg orally once daily, immediately after the same meal each day.
None Documented
None Documented
Dutasteride: Terminal half-life ~5 weeks (3-7 weeks), allowing once-daily dosing; steady-state reached at 3-6 months. Tamsulosin: Terminal half-life ~9-13 hours in healthy subjects, prolonged in elderly (up to 16-19 hours).
The terminal elimination half-life is approximately 5 to 9 hours in healthy young subjects, and 6 to 10 hours in elderly patients. This supports once-daily dosing, with steady state achieved after 3-5 days.
Dutasteride: 40% as metabolites in feces (mainly via bile), 5% in urine. Tamsulosin: 76% in urine as unchanged drug and metabolites, 24% in feces.
After oral administration, approximately 11% of the dose is excreted unchanged in urine, while 49% is excreted as metabolites in urine and 22% in feces. Overall, renal elimination accounts for about 60% of total clearance.
Category A/B
Category C
Alpha-1 Blocker
Alpha-1 Blocker